Loss of SLCO1B3 drives taxane resistance in prostate cancer

BACKGROUND: Both taxanes, docetaxel and cabazitaxel, are effective treatments for metastatic castration-resistant prostate cancer (mCRPC). However, resistance to taxanes is common. Our objective was to investigate mechanisms of taxane resistance in prostate cancer. METHODS: Two docetaxel-resistant p...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Main Authors: de Morrée, Ellen S, Böttcher, René, van Soest, Robert J, Aghai, Ashraf, de Ridder, Corrina M, Gibson, Alice A, Mathijssen, Ron HJ, Burger, Herman, Wiemer, Erik AC, Sparreboom, Alex, de Wit, Ronald, van Weerden, Wytske M
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Translational Therapeutics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5023781/
https://ncbi.nlm.nih.gov/pubmed/27537383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.251
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares